The Acute Repetitive Seizures Market is Predicted to Surge due to Rise in Epilepsy Cases

The acute repetitive seizures market involves therapeutics that provide effective treatment for acute repetitive seizures. These seizures involve recurrent seizure episodes that occur close together with limited recovery time between seizures. Acute repetitive seizures therapeutics aim to promptly stop seizures from continuing and allow time for recovery. Drugs such as benzodiazepines are commonly used for acute repetitive seizures as they work quickly to calm overactive neurons. Despite the availability of anti-epileptic drugs, emergency treatment is required for acute repetitive seizures due to recurrence of seizures.

The global acute repetitive seizures market is estimated to be valued at US$ 3.10 Bn in 2024 and is expected to exhibit a CAGR of 12.% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the acute repetitive seizures market are Neurelis, Inc., Bausch Health Companies Inc., Alexza Pharmaceuticals, Inc., VERITON PHARMA, UCB S.A., Takeda Pharmaceutical Company Limited, Pfizer Inc., Sanofi, GSK plc, Eisai Co., Ltd., H. Lundbeck A/S, Cognizance Biomarkers, LLC. Neurelis, Inc. offers VALTOCO which is a novel intranasal formulation of diazepam.

The growing prevalence of epilepsy around the world is a major factor driving the Acute Repetitive Seizures Market demand. According to the World Health Organization, close to 50 million people worldwide have epilepsy. This large pool of patients suffering from seizures creates significant requirements for emergency treatment options.

The market is also witnessing increased focus on global expansion strategies by major players. Companies are undertaking initiatives to increase presence across international markets and widen geographic coverage. Partnerships with local distributors help facilitate improved access to acute repetitive seizures drugs. This ensures treatments reach global epilepsy populations in a timely manner.

Market Key Trends

One of the key trends prevalent in the acute repetitive seizures market is the rising focus on new drug delivery methods. Players are investing in innovative drug delivery routes like intranasal sprays, buccal films, sublingual tablets to enable faster absorption and more immediate effects. For instance, Neurelis, Inc. offers the first U.S. FDA-approved intranasal diazepam spray which can help terminate acute repetitive seizures. Its intranasal delivery provides a rapid alternative to rectal gels or injectables for seizure emergencies.

Porter’s Analysis
Threat of new entrants: New companies will require large investments for R&D and clinical trials to build their product pipelines.
Bargaining power of suppliers: Suppliers have low bargaining power due to availability of substitute ingredients and focus on quality and reliability
Bargaining power of buyers: Buyers have moderate bargaining power due clients can switch between alternative treatments easily.
Threat of new substitutes: New treatment options pose a threat but require huge investments and longer time for approval.
Competitive rivalry: Intense competition exists between large pharmaceutical companies.

Geographically, In the Acute Repetitive Seizures Market Regional Analysis North America presently dominates the market due to factors such as the presence of advanced healthcare facilities and growing awareness regarding neurological disorders. Awareness programs by government agencies and non-profit organizations further drive the market.

The Asia Pacific region is anticipated to witness the fastest growth during the forecast period owing to rising healthcare expenditure, increasing awareness about epilepsy management and rising prevalence of neurological disorders due to hectic lifestyle in developing countries. Rising geriatric population also supports the market growth in Asia Pacific.

Geographical Regions
The acute repetitive seizures market is presently dominated by North America both in terms of value and volume. North America accounts for over 40% share of the global market owing to factors like presence of advanced healthcare facilities, growing awareness regarding neurological disorders, favourable reimbursement policies, new product launches etc. Awareness programs by government agencies as well as non-profit organizations also drive the market in North America.

Asia Pacific region is anticipated to witness the fastest growth during the forecast period from 2024 to 2031. Factors like rising healthcare expenditure, increasing awareness about epilepsy management, growing geriatric population and rising prevalence of neurological disorders due to drastic lifestyle changes in developing countries like India and China support the growth of this market in Asia Pacific. Countries like China, India, Japan and South Korea are expected to contribute significantly to the regional market. Improving healthcare infrastructure also provides growth opportunities in Asia Pacific region.

Get More Insights On Acute Repetitive Seizures Market

About Author:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)